Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies-Reference-Cited by-同舟云学术

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

Published:2014-11-03 Issue:4 Volume:22 Page:366-375
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Manns M. P.¹,Fried M. W.²,Zeuzem S.³,Jacobson I. M.⁴,Forns X.⁵,Poordad F.⁶,Peeters M.⁷,Fu M.⁷,Lenz O.⁷,Ouwerkerk-Mahadevan S.⁸,Jessner W.⁷,Scott J. A.⁹,Kalmeijer R.¹⁰,De La Rosa G.¹⁰,Sinha R.⁷,Beumont-Mauviel M.⁷

Affiliation:

1. Department of Gastroenterology, Hepatology and Endocrinology; Medizinische Hochschule Hannover; Hannover Germany

2. University of North Carolina at Chapel Hill; Chapel Hill NC USA

3. J.W. Goethe University Hospital; Frankfurt Germany

4. Weill Cornell Medical College; New York NY USA

5. Liver Unit; Hospital Clinic; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD); Barcelona Spain

6. Texas Liver Institute; University of Texas Health Science Center; San Antonio TX USA

7. Janssen Infectious Diseases BVBA; Beerse Belgium

8. Janssen Research & Development BVBA; Beerse Belgium

9. Janssen Global Services, LLC; High Wycombe UK

10. Janssen Global Services, LLC; Titusville NJ USA

Funder

Janssen

Genentech

Vertex

Abbott

Pfizer

Tibotec